General
Preferred name
NALDEMEDINE
Synonyms
Symproic ()
NALDEMEDINE TOSYLATE ()
S-297995 ()
Naldemedine (tosylate) ()
S-297995 (tosylate) ()
Naldemedine ()
Naldemedine tosilate ()
P&D ID
PD046720
CAS
1345728-04-2
916072-89-4
Tags
available
natural product
drug
Approved by
EMA
FDA
First approval
2017
Drug Status
investigational
approved
Drug indication
Opioid-induced constipation
Opioid dependence
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Naldemedine (S-297995) is a dual μ/δ opioid receptor antagonist, designed to act peripherally (peripherally acting mu-opioid receptor antagonist or PAMORA) . It is used clinically for its ability to counteract opioid agonist-induced adverse effects such as constipation, nausea, and vomiting. Naldemedine was developed by Shionogi Inc. It is the compound claimed in patent WO2013172297 with formula IA (17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid) . (GtoPdb)
DESCRIPTION Naldemedine is a μ opioid receptor antagonist, designed to act peripherally (peripherally acting mu-opioid receptor antagonist or PAMORA). It is being investigated for its ability to counteract opioid agonist-induced adverse effects such as constipation, nausea, and vomiting. Naldemedine is being developed by Shionogi Inc. It is the compound claimed in patent WO2013172297 with formula IA (17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide 4-methylbenzenesulfonic acid) .
Compound Sets
13
ChEMBL Approved Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ReFrame library
External IDs
34
Properties
(calculated by RDKit )
Molecular Weight
570.25
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
4
Rotatable Bonds
6
Ring Count
8
Aromatic Ring Count
3
cLogP
3.48
TPSA
141.18
Fraction CSP3
0.47
Chiral centers
4.0
Largest ring
6.0
QED
0.35
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Biosynthetic Origin
Alkaloid
Therapeutic Indication
Opioid Induced Constipation
Therapeutic Class
CNS & PNS
Pathway
GPCR/G protein
Neuronal Signaling
Target
Opioid Receptor
Source data